News of Note—Neurostimulation player ElectroCore bags $36M; Ethicon slammed with $57M pelvic mesh verdict

News of note

> ElectroCore, which markets a noninvasive vagus nerve stimulation device that treats pain associated with episodic cluster headaches, raised $36 million. SEC filing

> Johnson & Johnson’s Ethicon unit was ordered to pay $57.1 million in a pelvic mesh suit. Philadelphia Inquirer article

> The FDA cleared MyndTec’s functional electric stimulation system for the treatment of patients with upper extremity paralysis. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suggested Articles

The FDA granted an expanded indication to GT Medical’s GammaTile cancer therapy, broadening its use to newly diagnosed brain cancer patients.

A new company focusing on sperm rather than egg biology debuted with goals of increasing fertility rates and reducing pregnancy complications.

Verily has obtained a second agency green light for measuring irregular heartbeats using its prescription smartwatch.